Baxter International Inc.

Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. The company has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. It also has a strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs for cancer treatments, such as lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and side effects of chemotherapy. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.